Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.

  • Merck's first-in-class Zontivity cleared in US Merck's first-in-class Zontivity cleared in US

    After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1

  • FDA panel backs Merck's vorapaxar FDA panel backs Merck's vorapaxar

    Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia